At close: December 20 at 4:00:03 PM EST
After hours: December 20 at 6:21:07 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
28,326.00
7,163.00
--
6,254.00
79,105.00
Operating Expense
74,765.00
71,809.00
94,114.00
97,304.00
143,881.00
Operating Income
-46,439.00
-64,646.00
-94,114.00
-91,050.00
-64,776.00
Net Non Operating Interest Income Expense
6,074.00
3,451.00
1,022.00
302.00
2,624.00
Other Income Expense
5.00
--
--
-41,638.00
--
Pretax Income
-40,365.00
-61,195.00
-93,092.00
-132,386.00
-62,152.00
Tax Provision
439.00
33.00
--
-2,531.00
--
Net Income Common Stockholders
-40,804.00
-61,228.00
-93,092.00
-129,855.00
-62,152.00
Diluted NI Available to Com Stockholders
-40,804.00
-61,228.00
-93,092.00
-129,855.00
-62,152.00
Basic EPS
-6.89
-13.38
-23.04
-36.00
-21.00
Diluted EPS
-6.89
-13.38
-23.04
-36.00
-21.00
Basic Average Shares
5,701.24
4,577.37
4,034.11
3,606.70
2,952.26
Diluted Average Shares
5,701.24
4,577.37
4,034.11
3,606.70
2,952.26
Total Operating Income as Reported
-46,439.00
-64,646.00
-94,114.00
-132,688.00
-64,776.00
Total Expenses
74,765.00
71,809.00
94,114.00
97,304.00
143,881.00
Net Income from Continuing & Discontinued Operation
-40,804.00
-61,228.00
-93,092.00
-129,855.00
-62,152.00
Normalized Income
-40,804.00
-61,228.00
-93,092.00
-89,008.12
-62,152.00
Interest Income
6,074.00
3,451.00
1,022.00
302.00
2,624.00
Net Interest Income
6,074.00
3,451.00
1,022.00
302.00
2,624.00
EBIT
-46,439.00
-64,646.00
-94,114.00
-91,050.00
-64,776.00
EBITDA
-46,258.00
-64,196.00
-93,616.00
-90,584.00
-64,085.00
Reconciled Depreciation
181.00
450.00
498.00
466.00
691.00
Net Income from Continuing Operation Net Minority Interest
-40,804.00
-61,228.00
-93,092.00
-129,855.00
-62,152.00
Total Unusual Items Excluding Goodwill
--
--
--
-41,638.00
--
Total Unusual Items
--
--
--
-41,638.00
--
Normalized EBITDA
-46,258.00
-64,196.00
-93,616.00
-48,946.00
-64,085.00
Tax Rate for Calcs
0.00
0.00
--
0.00
--
Tax Effect of Unusual Items
--
--
--
-791.12
--
12/31/2020 - 12/17/2010
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
HLVX HilleVax, Inc.
1.8600
+1.64%
NXTC NextCure, Inc.
0.9700
+2.11%
AADI Aadi Bioscience, Inc.
3.3900
+46.12%
CLRB Cellectar Biosciences, Inc.
0.2350
-1.26%
SPRO Spero Therapeutics, Inc.
0.9551
-4.30%
CTMX CytomX Therapeutics, Inc.
1.0900
-0.91%
IPSC Century Therapeutics, Inc.
1.1000
+4.76%
EPIX ESSA Pharma Inc.
1.6000
0.00%
GLTO Galecto, Inc.
4.7000
+0.43%
KZR Kezar Life Sciences, Inc.
6.38
-2.15%